Humphrey Fonge, PhD
@theranosticslab
Cancer researcher and professor - Université Laval. Passionate about developing, translating and commercializing new cancer theranostics.
ID: 1268615315564437504
04-06-2020 18:47:33
14 Tweet
49 Takipçi
132 Takip Edilen
A #USaskResearch team, including Dr. Humphrey Fonge (Humphrey Fonge, PhD) and Dr. Changiz Taghibiglou (Dept. of Anatomy, Physiology and Pharmacology), are working to identify the lasting effects of concussion-related insulin resistance in the brain. medicine.usask.ca/news/2021/usas…
A @USask team including Dr. Humphrey Fonge (Humphrey Fonge, PhD) and Dr. Changiz Taghibiglou (Dept. of Anatomy, Physiology and Pharmacology), are working to identify the lasting effects of concussion-related insulin resistance in the brain. #Concussion news.usask.ca/articles/resea…
Save the date - the Controlled Release Society Annual Meeting is coming to Canada 🇨🇦. I look forward to connecting in-person with dear friends and colleagues. Our research group will be there in full force! Great science and good fun.
Septembre est le Mois de la sensibilisation au #cancerdelovaire. Soulignons les recherches des Drs Fonge et Uppalapati de University of Saskatchewan Research, qui visent à traiter le cancer de l’ovaire grâce à la théranostique. Humphrey Fonge, PhD 👨🏿🔬🔬 En savoir plus ➡️ cihr-irsc.gc.ca/f/53357.html
September is #OvarianCancerAwarenessMonth. Drs. Humphrey Fonge and Maruti Uppalapati from University of Saskatchewan Research are using precision theranostics (therapeutics and diagnostics) to treat ovarian cancer. Humphrey Fonge, PhD 👨🏿🔬🔬 Learn more ➡️ cihr-irsc.gc.ca/e/53357.html
🌟👏 CONGRATULATIONS to the 83 recipients of our Operating Grants! 🔬 Their research is the key to #OutsmartCancer! 👉 loom.ly/-Sq5GXA 🙏THANK YOU to our partners ! CIHR-ICR | IC-IRSC @CdnLiverFdtn Fondation cancer du sein du Québec Ovarian Cancer Canada Canadian Cancer Society Desjardins Insurance
💊 Dr. Humphrey Fonge's team (Humphrey Fonge, PhD) at Université Laval found that [225Ac]Ac-Macropa-trastuzumab-PEG6-DM1 is more potent than antibody-drug conjugates against trastuzumab-resistant breast cancer. 👉 Clinical Cancer Research | bit.ly/3P0mMXv